Skip to main content Accessibility help
×
Home

Cigarette smoking and schizophrenia

Published online by Cambridge University Press:  02 January 2018

Rights & Permissions[Opens in a new window]

Extract

It has been recognised for many years that patients with psychiatric illnesses, especially schizophrenia, smoke to excess. However, recently there has been a resurgence of interest in the high prevalence of nicotine addiction in patients with schizophrenia. It has become increasingly clear that heavy cigarette smoking is intimately associated with the schizophrenic illness and that this may have implications for the underlying neurobiology of schizophrenia.

Type
Research Article
Copyright
Copyright © The Royal College of Psychiatrists 2000 

It has been recognised for many years that patients with psychiatric illnesses, especially schizophrenia, smoke to excess. However, recently there has been a resurgence of interest in the high prevalence of nicotine addiction in patients with schizophrenia. It has become increasingly clear that heavy cigarette smoking is intimately associated with the schizophrenic illness and that this may have implications for the underlying neurobiology of schizophrenia.

Rates of cigarette smoking

The number of patients with schizophrenia who smoke is very high (see Box 1). One study reported the prevalence to be 88%, nearly three times the rate in the general population and higher than the elevated rates of smoking in patients with other psychiatric illnesses. The increased prevalence persists even after adjustment for marital status, alcohol use and socio-economic status (Reference Hughes, Hatsukami and MitchellHughes et al, 1986).

Box 1. Rates of smoking in schizophrenia

  1. The rate of smoking in people with schizophrenia is at least two to three times that in the general population

  2. Patients who smoke, smoke at heavier rates than in the general population

  3. Most patients start smoking in their teens, before the illness begins

A number of more recent cross-sectional studies from different countries have reported high rates of smoking in patients with schizophrenia (Reference Goff, Henderson and AmicoGoff et al, 1992; Reference Chong and ChooChong & Choo, 1996). One large study of 360 state hospital in-patients, of whom 237 were diagnosed as having schizophrenia or schizo-affective disorder, found that the overall prevalence of smoking was 85%, and 93% in young male patients with schizophrenia (Reference De Leon, Dadvand and CanusoDe Leon et al, 1995). Smoking occurs at much higher rates than other types of substance misuse or dependence, which have been shown also to be elevated among patients with schizophrenia.

In our own study (Reference Kelly and McCreadieKelly & McCreadie, 1999) we found that the average age when patients with schizophrenia started smoking was the same as in the general population, namely mid-teens; 90% of patients who smoked had started smoking before their illness began.

Patients with schizophrenia who smoke are also heavier smokers than those in the general population and those with other psychiatric disorders. In our own study, 68% of patients with schizophrenia who smoked were classed as heavy smokers (25 or more cigarettes daily) compared with only 11% of the general population who smoke. In another study (Reference Olincy, Young and FreedmanOlincy et al, 1997), patients with schizophrenia who smoked had much higher levels of the nicotine metabolite cotinine in comparison with other smokers, confirming our finding. Excessive smoking tends to be a lifelong habit among patients with schizophrenia. The proportion of those who quit is lower than in the general population; in our study of a population of patients with schizophrenia, only 8% of males were ex-smokers, compared with 31% of males in a local general population.

Why do patients with schizophrenia smoke?

Why do patients with schizophrenia smoke at these excessive rates? There are three possible explanations for the association: something about the illness leads patients to smoke; smoking is another risk factor for schizophrenia; or a third factor leads to both schizophrenia and smoking (see Box 2).

Box 2. Why do patients with schizophrenia smoke?

  1. Aspects of the illness might lead more patients to smoke

  2. Smoking might be an aetiological factor in schizophrenia

  3. Genetic and/or environmental factors might lead both to nicotine addiction and to schizophrenia

The first possibility has received most attention. It has been suggested that smoking may be a marker of a more severe illness process (Reference De LeonDe Leon, 1996). Smokers are more often young and male; they have an earlier onset of illness, increased numbers of hospital admissions and receive higher doses of neuroleptic medication (Reference Goff, Henderson and AmicoGoff et al, 1992; Reference Ziedonis, Kosten and GlazerZiedonis et al, 1994). In addition, smokers have more severe symptoms with higher scores on the Brief Psychiatric Rating Scale (Reference Overall and GorhamOverall & Gorham, 1962) for positive and negative symptoms (Reference Goff, Henderson and AmicoGoff et al, 1992; Reference Chong and ChooChong & Choo, 1996; Reference Ziedonis, Kosten and GlazerZiedonis et al, 1994).

Another suggestion is that patients smoke as a form of self-medication with nicotine, which may help regulate a dysfunctional mesolimbic dopamine system. It may increase dopamine release in the pre-frontal cortex and alleviate positive and negative symptoms (Reference Lavin, Siris and MasonLavin et al, 1996). Worsening of psychotic symptoms on nicotine withdrawal has been reported (Reference Dalack and Meador-WoodruffDalack & Meador-Woodruff, 1996). It has also been shown that nicotine administration enhances cognitive performance on a number of tasks. However, in general, patients with schizophrenia who smoke report similar reasons to other smokers (“addicted”, “relaxation” and “to calm down”), with only 17% of patients reporting that smoking improved psychotic symptoms.

As we have found that most patients who smoke began to do so before psychotic aspects of the illness appeared, premorbid characteristics are perhaps important. It is noteworthy that in our study patients who smoked were as children more poorly adjusted socially than those who were not smokers.

Patients with schizophrenia may smoke heavily as a result of antipsychotic medication, which produces marked dopamine receptor blockade. Possibly, a very high level of smoking is necessary to overcome this blockade and produce the reward effects. It has been shown that, compared with baseline, patients with schizophrenia smoke more after starting haloperidol (Reference McEvoy, Freudenreich and LevinMcEvoy et al, 1995). It has also been shown in a placebo-controlled study that after a single dose of haloperidol, normal subjects smoked significantly more during the following hour, as measured by blood nicotine levels (Reference Dawe, Gerada and RussellDawe et al, 1995).

A second explanation for the association between schizophrenia and smoking is that smoking acts as an aetiological risk factor for schizophrenia. It may be that repeated activation by nicotine of the mesolimbic system over a long time precipitates the onset of schizophrenia in vulnerable individuals. We found that the earlier the age of starting smoking, the earlier was the onset of psychotic illness in women (Reference Kelly and McCreadieKelly & McCreadie, 1999). Interestingly, nicotine acts like other drugs of addiction such as cocaine and amphetamine, activating the mesolimbic dopamine system (Reference Pontieri, Tanda and OrziPontieri et al, 1996); this effect appears to be of critical importance for the reinforcing and reward properties of the drug. Also, nicotine has been shown to increase burst activity in the dopamine neurons of the ventral tegmental area, a form of firing pattern of these cells that is physiologically associated with basic motivational processes underlying learning and cognition (Reference IversenIversen, 1996).

Third, genetic and/or environmental factors might predispose individuals to develop both schizophrenia and nicotine addiction. Much work in the genetics of both schizophrenia (Reference Maier and SchwabMaier & Schwab, 1998) and nicotine addiction (Reference ClarkeClarke, 1998) has focused on the dopamine receptor system.

Consequences of smoking

Morbidity and mortality

Smoking remains the single greatest preventable cause of death in our society. It appears to engender both general and specific health risks for patients with schizophrenia. There is no doubt that cigarette smoking causes considerable morbidity and mortality, but there are no epidemiological data addressing smoking-related morbidity and mortality in schizophrenia. Previous work has shown that among people with schizophrenia life expectancy is estimated as being 20% less than in the general population. There is an increase in deaths from natural causes and the most common causes are cardiovascular and respiratory disease, both smoking-related (Reference Mortensen and JuelMortensen & Juel, 1993). The markedly elevated prevalence of smoking is clearly an important potential factor in explaining the elevated mortality in schizophrenia.

Medication and side-effects

Smoking has been shown to decrease plasma levels of neuroleptics by inducing hepatic microsomal enzymes (Reference Salokangas, Saarijarvi and TaiminenSalokangas et al, 1997). Therefore, patients who smoke require larger doses of drugs than non-smokers to achieve the same therapeutic effect (Reference Lohr and FlynnLohr & Flynn, 1992). It has also been reported that smokers have been prescribed neuroleptics at twice the daily dose of non-smokers while exhibiting significantly less neuroleptic-induced parkinsonism. Spontaneous abnormal involuntary movements indistinguishable from tardive dyskinesia have also been reported in a general population sample of older males who smoke (Reference Nilsson, Waller and RosengrenNilsson et al, 1997). It would seem likely, therefore, that there is an association between tardive dyskinesia and smoking in schizophrenia. However, in three previous studies, only one showed that tardive dyskinesia was more prevalent among smokers (Reference Yassa, Lal and KorpassyYassa et al, 1987); two found no relationship (Reference Menza, Grossman and Van HornMenza et al, 1991; Reference Chiles, Cohen and RolandChiles et al, 1993).

Economic considerations

Cigarettes are not cheap. We have recently carried out some simple arithmetic in relation to smoking and schizophrenia (Reference McCreadie and KellyMcCreadie & Kelly, 2000). Our patients smoke on average 26 cigarettes per day. At £2.79 per packet, this works out at £1300 per year. Very few of our patients work. We reckon that probably up to one-third of state benefits is spent on cigarettes. Of the cost of a packet of cigarettes, 87% is tax. Thus, patients, through their smoking habits, are contributing very substantially to the cost of their own care.

Smoking cessation

Smoking cessation rates are poor in heavy smokers and even lower in those with psychiatric illness. Attempts to get patients with schizophrenia to stop smoking have met with only limited success. There is often a perception that it will be unsuccessful and will deprive individuals of one of their few pleasures. This view is inherently discriminatory. In our own study (Reference Kelly and McCreadieKelly & McCreadie, 1999) a third of patients reported that they wanted to quit for health reasons. Clearly, smokers with schizophrenia have a severe nicotine addiction, and pharmacological and psychological support with smoking cessation needs to be addressed.

Box 3. Management issues

  1. Smoking must be implicated in the increased mortality in schizophrenia

  2. Smokers require higher doses of antipsychotic medication

  3. A substantial proportion of the income of smokers with schizophrenia is spent on cigarettes

  4. Patients with schizophrenia have the right to be offered treatment for their nicotine addiction

There have been few studies that have looked at cessation methods (reviewed by Lavin et al, 1996). Smoking bans on in-patient psychiatric units have generated naturalistic reports; usually the most severely addicted patients are extremely resourceful and continue to smoke. Smoking cessation groups, nicotine gum, nicotine patches and clonidine patches have all been tried with both in-patients and out-patients, with poor results. For example, the six-month cessation rate was only 12-13% with group therapy alone (Reference Addington, el-Guebaly and CampbellAddington et al, 1998) or in combination with nicotine reduction therapy (Reference Ziedonis and GeorgeZiedonis & George, 1997). Outcome studies are urgently necessary to evaluate the effectiveness of smoking cessation programmes (e.g. in-patient v. out-patient programmes, nicotine replacement, behavioural techniques and so on). For the severely addicted, the following combinations may be tried: combined gum and patch therapy; bupropion and nicotine patch; nicotine nasal spray; or nicotine inhaler (details available from the author upon request).

The use of bupropion is interesting. In normal subjects, sustained-release bupropion, an antidepressant, alone or in combination with a nicotine patch, resulted in significantly higher long-term rates of smoking cessation (30.3 and 35.5%, respectively) than use of either the nicotine patch alone (16.4%) or placebo (15.6%) (Reference Jorenby, Leischow and NidesJorenby et al, 1999). In a recent case report (Reference Evins and TisdaleEvins & Tisdale, 1999), sustained-release bupropion was successfully used with a chronically ill male patient with schizophrenia. Why might an antidepressant such as bupropion be helpful in smoking cessation? It has been suggested that long-term administration of bupropion and nortriptyline, adrenergic antidepressants, produces a significantly increased responsivity to stimulation of the ventral tegmental dopamine cells. This is not seen with selective serotonin reuptake inhibitors (SSRIs). This may be why buproprion and nortriptyline but not SSRIs increase smoking abstinence. For a fuller comment on this possibility, see Glassman (1998).

We have recently reported (Scottish Schizophrenia Research Group, 2000) that the prevalence of smoking in first-episode patients is just as high as in chronic patients, but that the number of cigarettes smoked per day is no higher than that in smokers in the general population. Perhaps it is at this early stage that attempts to help patients to stop smoking should be made.

In conclusion, despite the often limited resources of patients with schizophrenia, they commonly view cigarette smoking as a necessity. Most patients with schizophrenia smoke at high rates and few manage to stop. This dramatically elevated prevalence of smoking among individuals with schizophrenia raises the intriguing possibility that nicotine use and schizophrenia have some shared underlying neurobiology.

Multiple choice questions

  1. 1. Patients with schizophrenia who smoke:

    1. a smoke at rates higher than those with other psychiatric conditions

    2. b in the early stages of the illness smoke more cigarettes daily than general population smokers

    3. c start smoking at a later age than general population smokers

    4. d quit at the same rates as general population smokers.

  2. 2. Nicotine may:

    1. a regulate a dysfunctional mesolimbic dopamine system

    2. b improve psychiatric symptoms on withdrawal

    3. c impair cognitive performance

    4. d prevent relapse.

  3. 3. Smoking cessation in schizophrenia:

    1. a can be achieved more readily than in other psychiatric conditions

    2. b is unwanted by more than two-thirds of patients themselves

    3. c should probably be attempted at the early stages of the illness

    4. d might include combined nicotine gum and patch therapy.

MCQ answers

1 2 3
a T a T a F
b F b F b F
c F c F c T
d F d F d T

References

Addington, J., el-Guebaly, N., Campbell, W. et al (1998) Smoking cessation treatment for patients with schizophrenia. American Journal of Psychiatry, 155, 974976.CrossRefGoogle ScholarPubMed
Chiles, J. A., Cohen, S., Roland, M. et al (1993) Smoking and schizophrenic psychopathology. American Journal of Addictions, 2, 315319.CrossRefGoogle Scholar
Chong, S. A. & Choo, H. L. (1996) Smoking among Chinese patients with schizophrenia. Australian and New Zealand Journal of Psychiatry, 30, 350353.CrossRefGoogle ScholarPubMed
Clarke, P. B. S. (1998) Tobacco smoking, genes and dopamine. Lancet, 353, 8485.CrossRefGoogle Scholar
Dalack, G. W. & Meador-Woodruff, J. H. (1996) Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophrenia Research, 22, 133141.CrossRefGoogle Scholar
Dawe, S., Gerada, C., Russell, M. A. et al (1995) Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology, 117, 110115.CrossRefGoogle ScholarPubMed
De Leon, J. (1996) Smoking and vulnerability for schizophrenia. Schizophrenia Bulletin, 22, 405409.CrossRefGoogle Scholar
De Leon, J., Dadvand, M., Canuso, C. et al (1995) Schizophrenia and smoking: an epidemiological survey in a state hospital. American Journal of Psychiatry, 152, 453455.Google Scholar
Evins, A. E. & Tisdale, T. (1999) Bupropion and smoking cessation. American Journal of Psychiatry, 156, 798799.Google ScholarPubMed
Glassman, A. H. (1998) Psychiatry and cigarettes. Archives of General Psychiatry, 55, 692693.CrossRefGoogle ScholarPubMed
Goff, D. C., Henderson, D. C. & Amico, E. (1992) Cigarette smoking in schizophrenia: relationship to psychopathology and medication side-effects. American Journal of Psychiatry, 149, 11891194.Google ScholarPubMed
Hughes, J. R., Hatsukami, D. K., Mitchell, J. E. et al (1986) Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry, 143, 993997.Google ScholarPubMed
Iversen, L. L. (1996) Smoking … harmful to the brain. Nature, 382, 206207.CrossRefGoogle Scholar
Jorenby, D. E., Leischow, S. J., Nides, M. A. et al (1999) A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine, 304, 685691.CrossRefGoogle Scholar
Kelly, C. & McCreadie, R. G. (1999) Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. American Journal of Psychiatry, 156, 17511757.Google ScholarPubMed
Lavin, M. R., Siris, S. G. & Mason, S. E. (1996) What is the clinical importance of cigarette smoking in schizophrenia? American Journal of Addictions, 5, 189208.CrossRefGoogle Scholar
Lohr, J. B. & Flynn, K. (1992) Smoking and schizophrenia. Schizophrenia Research, 8, 93102.CrossRefGoogle Scholar
McCreadie, R. G. & Kelly, C. (2000) Patients with schizophrenia who smoke. Private disaster, public resource. British Journal of Psychiatry, 176, 109.CrossRefGoogle ScholarPubMed
McEvoy, J. P., Freudenreich, O., Levin, E. D. et al (1995) Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology, 119, 124126.CrossRefGoogle ScholarPubMed
Maier, W. & Schwab, S. (1998) Molecular genetics of schizophrenia. Current Opinion in Psychiatry, 11, 1925.CrossRefGoogle Scholar
Menza, M. A., Grossman, N., Van Horn, M. et al (1991) Smoking and movement disorders in psychiatric patients. Biological Psychiatry, 30, 109115.CrossRefGoogle ScholarPubMed
Mortensen, P. B. & Juel, K. (1993) Mortality and causes of death in first admitted schizophrenic patients. British Journal of Psychiatry, 163, 183189.CrossRefGoogle ScholarPubMed
Nilsson, A., Waller, L., Rosengren, A. et al (1997) Cigarette smoking is associated with abnormal involuntary movements in the general male population. Biological Psychiatry, 41, 717723.CrossRefGoogle ScholarPubMed
Olincy, A., Young, D. A. & Freedman, R. (1997) Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biological Psychiatry, 42, 15.CrossRefGoogle ScholarPubMed
Overall, J. E. & Gorham, D. R. (1962) The brief psychiatric rating scale. Psychological Reports, 10, 799812.CrossRefGoogle Scholar
Pontieri, F. E., Tanda, G., Orzi, F. et al (1996) Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature, 382, 255256.CrossRefGoogle ScholarPubMed
Salokangas, R. K. R., Saarijarvi, S., Taiminen, T. et al (1997) Effect of smoking on neuroleptics in schizophrenia. Schizophrenia Research, 23, 5560.CrossRefGoogle Scholar
Scottish Schizophrenia Research Group (2000) Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated first-episode patients with schizophrenia. Preliminary report. British Journal of Psychiatry, 176, 290293.CrossRefGoogle Scholar
Yassa, R., Lal, S., Korpassy, A. et al (1987) Nicotine exposure and tardive dyskinesia. Biological Psychiatry, 22, 6772.CrossRefGoogle ScholarPubMed
Ziedonis, D. M., Kosten, T. R., Glazer, W. M. et al (1994) Nicotine dependence and schizophrenia. Hospital and Community Psychiatry, 45, 204206.Google Scholar
Ziedonis, D. M. & George, T. P. (1997) Schizophrenia and nicotine use: report of a pilot smoking cessation programme and review of neurobiological and clinical issues. Schizophrenia Bulletin, 23, 247254.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.

Altmetric attention score

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 568
Total number of PDF views: 977 *
View data table for this chart

* Views captured on Cambridge Core between 02nd January 2018 - 17th January 2021. This data will be updated every 24 hours.

Access
Hostname: page-component-77fc7d77f9-cctwg Total loading time: 0.799 Render date: 2021-01-17T16:31:06.900Z Query parameters: { "hasAccess": "1", "openAccess": "0", "isLogged": "0", "lang": "en" } Feature Flags last update: Sun Jan 17 2021 15:55:04 GMT+0000 (Coordinated Universal Time) Feature Flags: { "metrics": true, "metricsAbstractViews": false, "peerReview": true, "crossMark": true, "comments": true, "relatedCommentaries": true, "subject": true, "clr": true, "languageSwitch": true, "figures": false, "newCiteModal": false, "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true }

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Cigarette smoking and schizophrenia
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Cigarette smoking and schizophrenia
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Cigarette smoking and schizophrenia
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *